Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Serplulimab - Shanghai Henlius Biotech

Drug Profile

Serplulimab - Shanghai Henlius Biotech

Alternative Names: Anti-PD-1 monoclonal antibody - Shanghai Henlius Biotech; Anti-PD-I mAb - Shanghai Henlius Biotech; Han Si Zhuang; HANSIZHUANG; HLX-10; Recombinant humanized anti-PD-1 monoclonal antibody - Shanghai Henlius Biotech; Zerpidio

Latest Information Update: 19 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Henlix Biotech
  • Developer Henlix Biotech; PT Kalbe Genexine Biologics; Shanghai Henlius Biotech
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Oesophageal cancer; Small cell lung cancer; Solid tumours
  • Phase III Gastric cancer
  • Phase II/III Colorectal cancer
  • Phase II Cervical cancer; Hepatitis B; Liver cancer; Nasopharyngeal cancer; Squamous cell cancer
  • Preclinical Lymphoma

Most Recent Events

  • 13 Mar 2024 Serplulimab receives Innovation Passport designation through the Innovative Licensing and Access Pathway (ILAP) in UK
  • 31 Jan 2024 Shanghai Henlius Biotech completes a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) (IV) in China (NCT05400265)
  • 25 Jan 2024 Launched for Small cell lung cancer in Indonesia (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top